Hospital variation of 30-day readmission rate following transcatheter aortic valve implantation.


Journal

Heart (British Cardiac Society)
ISSN: 1468-201X
Titre abrégé: Heart
Pays: England
ID NLM: 9602087

Informations de publication

Date de publication:
02 2022
Historique:
received: 06 11 2020
revised: 04 02 2021
accepted: 08 02 2021
pubmed: 26 2 2021
medline: 30 4 2022
entrez: 25 2 2021
Statut: ppublish

Résumé

Thirty-day readmission rate is one of the hospital quality metrics. Outcomes of transcatheter aortic valve implantation (TAVI) have improved significantly, but it remains unclear whether hospital-level variance in 30-day readmission rate exists in the contemporary TAVI era. From the 2017 US Nationwide Readmission Database, endovascular TAVI were identified. The unadjusted 30-day readmission rate and 30-day risk-standardised readmission rate (RSRR) were calculated and we then conducted model testing to determine the relative contribution of hospital characteristics, patient-level covariates and economic status to the variation in readmission rates observed between the hospitals. A total of 44 899 TAVI from 338 hospitals were identified. The range of unadjusted 30-day readmission rate and 30-day RSRR was 2.0%-33.3% and 9.4%-15.3%, respectively. Median 30-day RSRR was 11.8% and there was a significant hospital-level variation (median OR 1.22, 95% CI 1.16 to 1.32, p<0.01) and this was similar in both readmissions caused due to major cardiac and non-cardiac conditions. Patient, hospital and economic factors accounted for 9.6%, 1.9% and 3.8% of the variability in hospital readmission rate, respectively. There was significant hospital-level variation in 30-day RSRR following TAVI. Further measures are required to mitigate this variance in the readmission rate.

Identifiants

pubmed: 33627399
pii: heartjnl-2020-318583
doi: 10.1136/heartjnl-2020-318583
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

219-224

Informations de copyright

© Author(s) (or their employer(s)) 2022. No commercial re-use. See rights and permissions. Published by BMJ.

Déclaration de conflit d'intérêts

Competing interests: None declared.

Auteurs

Tomo Ando (T)

Division of Cardiology, Kawasaki Saiwai Hospital, Kawasaki, Japan andotomo@hotmail.co.jp.

Said Ashraf (S)

Division of Interventional Cardiology, New York University Langone Medical Center, New York City, New York, USA.

Toshiki Kuno (T)

Department of Internal Medicine, Mount Sinai Beth Israel Hospital, New York City, New York, USA.

Alexandros Briasoulis (A)

Division of Cardiology, University of Iowa, Iowa City, Iowa, USA.

Hisato Takagi (H)

Division of Cardiovascular Surgery, Shizuoka Medical Center, Shizuoka, Japan.

Cindy Grines (C)

Division of Interventional Cardiology, Northside Hospital Cardiovascular Institute, Atlanta, Georgia, USA.

Aaqib Malik (A)

Division of Cardiology, Westchester Medical Center and New York Medical College, Valhalla, New York, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH